AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 173 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $695 | +97.4% | 16,123 | +34.1% | 0.00% | +50.0% |
| Q1 2024 | $352 | +31.3% | 12,023 | 0.0% | 0.00% | +100.0% |
| Q4 2023 | $268 | +18.6% | 12,023 | +31.8% | 0.00% | 0.0% |
| Q3 2023 | $226 | -12.4% | 9,123 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $258 | +22.9% | 9,123 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $210 | -18.0% | 9,123 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $256 | -99.9% | 9,123 | +21.3% | 0.00% | +100.0% |
| Q3 2022 | $213,000 | -37.5% | 7,523 | -35.8% | 0.00% | -50.0% |
| Q1 2022 | $341,000 | -11.4% | 11,723 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $385,000 | -28.8% | 11,723 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $541,000 | -16.3% | 11,723 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $646,000 | -13.3% | 11,723 | -18.7% | 0.00% | -25.0% |
| Q1 2021 | $745,000 | +84.4% | 14,423 | +54.7% | 0.00% | +100.0% |
| Q4 2020 | $404,000 | -89.7% | 9,323 | -91.7% | 0.00% | -93.1% |
| Q3 2020 | $3,910,000 | -70.9% | 111,723 | -55.5% | 0.03% | -49.1% |
| Q2 2020 | $13,426,000 | +367.2% | 251,046 | +209.9% | 0.06% | -8.1% |
| Q1 2020 | $2,874,000 | +7.5% | 81,000 | +44.6% | 0.06% | +34.8% |
| Q4 2019 | $2,674,000 | -47.1% | 56,000 | -64.1% | 0.05% | -54.9% |
| Q3 2019 | $5,054,000 | -45.5% | 156,000 | -16.1% | 0.10% | -40.7% |
| Q2 2019 | $9,278,000 | -26.0% | 186,000 | 0.0% | 0.17% | -29.2% |
| Q1 2019 | $12,544,000 | +39.5% | 186,000 | -4.6% | 0.24% | +34.3% |
| Q4 2018 | $8,991,000 | -66.4% | 195,000 | -43.8% | 0.18% | -45.0% |
| Q3 2018 | $26,760,000 | +95.5% | 347,000 | +113.5% | 0.33% | +22.3% |
| Q2 2018 | $13,687,000 | -22.2% | 162,500 | -24.4% | 0.27% | +47.0% |
| Q1 2018 | $17,582,000 | +215.4% | 215,000 | +120.5% | 0.18% | +177.3% |
| Q4 2017 | $5,574,000 | -14.4% | 97,500 | 0.0% | 0.07% | -19.5% |
| Q3 2017 | $6,508,000 | +23.4% | 97,500 | -4.9% | 0.08% | -39.3% |
| Q2 2017 | $5,274,000 | +351.5% | 102,500 | +412.5% | 0.14% | +321.9% |
| Q1 2017 | $1,168,000 | – | 20,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |